Timothy S. Pardee, MD, PhD, is a practicing hematologist and medical oncologist with a clinical focus on acute and chronic leukemias; associate professor of internal medicine, section on hematology/oncology and cancer biology; director of leukemia translational research; and co-leader of the hematology disease-oriented group at Wake Forest University Medical School. In addition to his clinical duties, Dr. Pardee heads an NCI-funded research program focused on the role of cellular metabolism in leukemia cell survival and resistance to therapy as well as novel therapeutics. He is active in clinical trials with a specific interest in the development of CPI-613, a first-in-class mitochondrial metabolism inhibitor. He conducted and published the first-in-human phase I clinical trial using CPI-613—building on clinical and preclinical work—he then completed a phase I trial of this agent in combination with high-dose cytarabine and mitoxantrone for patients with relapsed or refractory acute myeloid leukemia.
Dr. Pardee is an active member of the Leukemia Correlative Science Committee for the Alliance for Clinical Trials in Oncology, and a recipient of numerous teaching and clinical awards including recognition in the “Best Doctors in America List” (2015-2016, 2017-2018); a 2015 Master Teacher Award from the house staff of the Department of Medicine at Wake Forest University; and the 2016 Best Teacher and Role Model Award from the third year medical school class. He was awarded a KO8 in 2012 for his work in AML metabolism and novel therapeutics, and in 2016, an R01. He continues to work clinically and preclinically to bring better treatments to patients suffering from acute and chronic leukemias.